Pparg-KO Mouse
一般名
Pparg-KO
製品ID
S-KO-03748
背景情報
C57BL/6JCya
系統ID
KOCMP-19016-Pparg-B6J-VB
状況
このマウス系統を論文で使用する場合は、「Pparg-KO Mouse（カタログ番号S-KO-03748）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Pparg-KO
系統ID
KOCMP-19016-Pparg-B6J-VB
遺伝子名
製品ID
S-KO-03748
遺伝子別名
Nr1c3, PPARgamma, PPAR-gamma, PPARgamma2, PPAR-gamma2
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 6
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000000450
NCBIトランスクリプトID
NM_011146.3
ターゲット領域
Exon 4
有効領域の大きさ
~1.1 kb
遺伝子研究の概要
Pparg, peroxisome proliferator-activated receptor gamma, is a receptor crucial for controlling cellular metabolism. It regulates the function of immune and stromal cells and is involved in multiple biological processes, such as anti-inflammatory and neuroprotective pathways, as well as lipid and glucose metabolism [1,2]. Genetic studies on its polymorphisms have been used to explore its role in diseases [4-6].
In rheumatoid arthritis (RA), PPARG promotes autophagy to accelerate reactive oxygen species (ROS) clearance, inhibiting ROS-mediated macrophage polarization and NLRP3 inflammasome activation, thus alleviating inflammation. CBD can act as a PPARG agonist to mitigate RA's inflammatory progression [1]. In major depression, the PPARg system has anti-inflammatory and neuroprotective effects in the CNS, increasing BDNF levels, promoting neuroplasticity and neurogenesis, and potentially having antidepressant effects [2]. In adrenal Cushing's syndrome, PPARG and related genes are downregulated, and its activator rosiglitazone decreases cell viability and steroid production, suggesting its potential as a therapeutic target [3]. For type 2 diabetes mellitus (T2DM), the rs1801282 (Pro12Ala) variant in PPARG is associated with a decreased risk of T2DM, and patients with the Ala12 variant may respond better to thiazolidinediones treatment [4,5]. In bladder cancer, Pparg signaling controls cancer subtype and immune exclusion, being downregulated in basal (muscle-invasive) and amplified in luminal (non-muscle-invasive) subtypes [6]. In psoriasis vulgaris, enhanced PPARG gene expression is a protective factor, indicating it as a potential therapeutic target [7]. In hypopharyngeal squamous cell carcinoma (HSCC), PPARG may promote chemosensitivity, likely by affecting cell proliferation and motility pathways [8].
In summary, Pparg plays essential roles in multiple biological processes and disease conditions. Studies on its genetic variants and functions in various disease models, especially in relation to inflammation, metabolism, and cancer, have provided insights into potential therapeutic strategies targeting Pparg.
References:
1. Geng, Qishun, Xu, Jiahe, Cao, Xiaoxue, Jia, Lansi, Xiao, Cheng. 2024. PPARG-mediated autophagy activation alleviates inflammation in rheumatoid arthritis. In Journal of autoimmunity, 146, 103214. doi:10.1016/j.jaut.2024.103214. https://pubmed.ncbi.nlm.nih.gov/38648706/
2. Gold, Philip W. 2021. The PPARg System in Major Depression: Pathophysiologic and Therapeutic Implications. In International journal of molecular sciences, 22, . doi:10.3390/ijms22179248. https://pubmed.ncbi.nlm.nih.gov/34502154/
3. Vetrivel, Sharmilee, Tamburello, Mariangela, Oßwald, Andrea, Sbiera, Silviu, Riester, Anna. 2023. PPARG dysregulation as a potential molecular target in adrenal Cushing's syndrome. In Frontiers in endocrinology, 14, 1265794. doi:10.3389/fendo.2023.1265794. https://pubmed.ncbi.nlm.nih.gov/38098864/
4. Sarhangi, Negar, Sharifi, Farshad, Hashemian, Leila, Aghaei Meybodi, Hamid Reza, Hasanzad, Mandana. 2020. PPARG (Pro12Ala) genetic variant and risk of T2DM: a systematic review and meta-analysis. In Scientific reports, 10, 12764. doi:10.1038/s41598-020-69363-7. https://pubmed.ncbi.nlm.nih.gov/32728045/
5. Jang, Eun Jeong, Lee, Da Hoon, Im, Sae-Seul, Yee, Jeong, Gwak, Hye Sun. 2023. Correlation between PPARG Pro12Ala Polymorphism and Therapeutic Responses to Thiazolidinediones in Patients with Type 2 Diabetes: A Meta-Analysis. In Pharmaceutics, 15, . doi:10.3390/pharmaceutics15061778. https://pubmed.ncbi.nlm.nih.gov/37376225/
6. Tate, Tiffany, Xiang, Tina, Wobker, Sarah E, Mckiernan, James M, Mendelsohn, Cathy Lee. 2021. Pparg signaling controls bladder cancer subtype and immune exclusion. In Nature communications, 12, 6160. doi:10.1038/s41467-021-26421-6. https://pubmed.ncbi.nlm.nih.gov/34697317/
7. Xue, Yan, Xia, Yuning, Cheng, Donghao, Mei, Ping, Hong, Sheng. 2024. Association between genetically proxied PPARG activation and psoriasis vulgaris: a Mendelian randomization study. In The Journal of dermatological treatment, 35, 2381763. doi:10.1080/09546634.2024.2381763. https://pubmed.ncbi.nlm.nih.gov/39034037/
8. Lian, Meng, Chen, Jiaming, Shen, Xixi, Hou, Lizhen, Fang, Jugao. 2020. Pparg may Promote Chemosensitivity of Hypopharyngeal Squamous Cell Carcinoma. In PPAR research, 2020, 6452182. doi:10.1155/2020/6452182. https://pubmed.ncbi.nlm.nih.gov/32373170/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。